January 17, 2025 10:23 AM EST

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Elizabeth Cairns

Senior biopharma journalist

Following the poorer-than-hoped performance of CagriSema last month, Novo Nordisk needed an emphatic clinical success with its high-dose version of Wegovy. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Ozempic makes list for next round of Medicare drug price negotiations

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

Broad Institute paper offers potential new framework for treating Huntington’s disease

AstraZeneca wins BTK race to market in first-line mantle cell lymphoma

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

Senior biopharma journalist

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted